Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Long-term Presence of CD19 CAR T Cells in B Cell Lymphomas

  • By

  • Luca Paruzzo

  • Emeline R. Chong

  • Elise A. Chong

  • Zhixuan Zheng

  • Puneeth Guruprasad

  • Daniel J. Landsburg

  • Sunita D. Nasta

  • Federico Stella

  • Ranjani Ramasubramanian

  • Vitor B. de Souza

  • Mohannad H. Alkhatib

  • Matthew Ho

  • Antonio Imparato

  • Gregory M. Chen

  • Don L. Siegel

  • Gabriela Plesa

  • Anlan Dai

  • Shane Mackey

  • Priyamvada Das

  • Peter Michener

  • Julie Jadlowsky

  • Frederic D. Bushman

  • Vrutti Patel

  • Alberto Carturan

  • Ellen B. Napier

  • Vanessa E. Gonzalez

  • Danuta Jarocha

  • Rong Xu

  • Bruce L. Levine

  • Patrizia Porazzi

  • Noelle Frey

  • David L. Porter

  • Jakub Svoboda

  • Joseph A. Fraietta

  • Carl H. June

  • Stephen J. Schuster

  • Marco Ruella

  • August 26, 2026

Share

Correction Notice: Long-term Presence of CD19 CAR T Cells in B Cell Lymphomas

Overview

This correction notice addresses inaccuracies in the labeling of figures in the original article on CD19 CAR T cells. Specifically, the y-axis labels in certain figures were corrected from 'log10(Padj)' to '–log10(Padj)'.

Background

CD19-targeted chimeric antigen receptor (CAR) T cell therapy has been utilized in the treatment of relapsed/refractory B-cell lymphomas. Accurate data presentation is crucial for the interpretation of clinical outcomes.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

  • The correction affects the y-axis labels in Fig. 3c, g and Fig. 5c of the original article.
  • Accurate data representation is essential for research integrity.

Clinical Implications

Healthcare professionals should reference the corrected figures when interpreting the data on CD19 CAR T cells.

Conclusion

The correction highlights the need for precise data presentation in clinical research.

Related Resources & Content

  1. Nature Medicine, 2026 -- Correction Notice: Long-term Presence of CD19 CAR T Cells in B Cell Lymphomas
  2. The ASCO Post — Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
  3. The ASCO Post — Long-Term Follow-up of Anti-CD19 CAR T-Cell Therapy in Relapsed B-Cell Malignancies
  4. Blood Cancer Journal — Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
  5. Blood Cancer Journal — Correction: Bispecific CAR-T Cells Targeting CD19 and CD22 in Adults with MRD-Positive B Cell Acute Lymphoblastic Leukemia: Phase I Clinical Trial Findings
  6. Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
  7. Long-Term Follow-up of Anti-CD19 CAR T-Cell Therapy in Relapsed B-Cell Malignancies
  8. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  9. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
  10. Decade-long persistence of CD19 CAR T cells in B cell lymphomas | Nature Medicine

Original Source(s)

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

  • by Luca Paruzzo, Emeline R. Chong, Elise A. Chong, Zhixuan Zheng, Puneeth Guruprasad, Daniel J. Landsburg, Sunita D. Nasta, Federico Stella, Ranjani Ramasubramanian, Vitor B. de Souza, Mohannad H. Alkhatib, Matthew Ho, Antonio Imparato, Gregory M. Chen, Don L. Siegel, Gabriela Plesa, Anlan Dai, Shane Mackey, Priyamvada Das, Peter Michener, Julie Jadlowsky, Frederic D. Bushman, Vrutti Patel, Alberto Carturan, Ellen B. Napier, Vanessa E. Gonzalez, Danuta Jarocha, Rong Xu, Bruce L. Levine, Patrizia Porazzi, Noelle Frey, David L. Porter, Jakub Svoboda, Joseph A. Fraietta, Carl H. June, Stephen J. Schuster, Marco Ruella

  • August 26, 2026

Related Content

Anatomical site and histological subtype as determinants of Breslow thickness and high-risk features in surgically managed cutaneous melanoma at Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence

Editorial: Multi-omics interrogation of tumor-associated macrophages: paving the way for next-generation cancer immunotherapies